Integrin Binding Peptide

Integrin Binding Peptide;

Integrin Binding Peptide 衍生自纤连蛋白。Integrin Binding Peptide 可用于制备 PEG 水凝胶。

Integrin Binding Peptideamp;;

Integrin Binding Peptide Chemical Structure

CAS No. : 278792-07-7

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation[1][2].

分子量

1066.11

Formula

C42H63N15O16S

CAS 号

278792-07-7

Sequence Shortening

Ac-GCGYGRGDSPG-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Raeber GP, et, al. Molecularly engineered PEG hydrogels: a novel model system for proteolytically mediated cell migration. Biophys J. 2005 Aug; 89(2): 1374-88.

    [2]. Kraehenbuehl TP, et, al. Three-dimensional extracellular matrix-directed cardioprogenitor differentiation: systematic modulation of a synthetic cell-responsive PEG-hydrogel. Biomaterials. 2008 Jun;29(18):2757-66.

Calmodulin Binding Peptide 1

Calmodulin Binding Peptide 1;

Calmodulin Binding Peptide 1 是一种来源于平滑肌肌球蛋白轻链激酶 (MLCK 肽) 的高亲和力 (pM) CaM 结合肽,能强烈抑制 IP3 诱导的 Ca2+ 释放。

Calmodulin Binding Peptide 1amp;;

Calmodulin Binding Peptide 1 Chemical Structure

CAS No. : 104041-80-7

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Calmodulin Binding Peptide 1 is a high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase (MLCK peptide), which strongly inhibits IP3-induced Ca2+ release [1].

分子量

5301.10

Formula

C231H373N69O70S2

CAS 号

104041-80-7

Sequence

Gly-Val-Met-Pro-Arg-Glu-Glu-Thr-Asp-Ser-Lys-Thr-Ala-Ser-Pro-Trp-Lys-Ser-Ala-Arg-Leu-Met-Val-His-Thr-Val-Ala-Thr-Phe-Asn-Ser-Ile-Lys-Glu-Leu-Asn-Glu-Arg-Trp-Arg-Ser-Leu-Gln-Gln-Leu-Ala

Sequence Shortening

GVMPREETDSKTASPWKSARLMVHTVATFNSIKELNERWRSLQQLA

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. González-Andrade M, et al. Importance of the interaction protein-protein of the CaM-PDE1A and CaM-MLCK complexes in the development of new anti-CaM drugs. J Mol Recognit. 2013 Apr;26(4):165-74.

Fibrinogen-Binding Peptide

Fibrinogen-Binding Peptide;

Fibrinogen-Binding Peptide 是一种通过抗完全性假说设计的纤维蛋白原受体上玻连蛋白结合位点的假定肽模拟物。Fibrinogen-Binding Peptide 结合纤维蛋白原,抑制血小板对纤维蛋白原的粘附和血小板聚集,也抑制血小板对氟噻嗪的粘附。

Fibrinogen-Binding Peptideamp;;

Fibrinogen-Binding Peptide Chemical Structure

CAS No. : 137235-80-4

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin[1].

分子量

565.62

Formula

C25H39N7O8

CAS 号

137235-80-4

Sequence

Glu-His-Ile-Pro-Ala

Sequence Shortening

EHIPA

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Gartner TK, et al. The peptide Glu-His-Ile-Pro-Ala binds fibrinogen and inhibits platelet aggregation and adhesion to fibrinogen and vitronectin. Proc Soc Exp Biol Med. 1991 Oct;198(1):649-55.

Fibrinogen Binding Inhibitor Peptide

Fibrinogen Binding Inhibitor Peptide; 纯度: 98.41%

Fibrinogen Binding Inhibitor Peptide 是一种十二肽 (HHLGGAKQAGDV,H12),是纤维蛋白原 γ 链羧基末端序列 (γ400-411)。是活化糖蛋白 (GP) IIb/IIIa 配体的特异性结合位点。

Fibrinogen Binding Inhibitor Peptideamp;;

Fibrinogen Binding Inhibitor Peptide Chemical Structure

CAS No. : 89105-94-2

规格 价格 是否有货 数量
1 mg ¥800 In-stock
5 mg ¥1900 In-stock
10 mg ¥3200 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Fibrinogen Binding Inhibitor Peptide 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cardiovascular Disease Compound Library
  • Peptide Library

生物活性

Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.

体外研究
(In Vitro)

Glycoprotein (GP) IIb/IIIa, which exists on the membrane of platelets, changes its form from inactive to active when platelets adhere to collagen exposed on sites of vascular injury. In the circulation, platelet aggregation is mediated by fibrinogen by bridging adjacent platelets through GPIIb/IIIa in an activation-dependent manner. A dodecapeptide HHLGGAKQAGDV (H12), corresponding to the fibrinogen γ-chain carboxy-terminal sequence (γ400-411), is a specific binding site of the ligand for activated GPIIb/IIIa[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1189.28

Formula

C50H80N18O16

CAS 号

89105-94-2

Sequence

His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val

Sequence Shortening

HHLGGAKQAGDV

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Okamura Y, et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membraneproperties and their hemostatic effects as a platelet substitute. J Control Release. 2010 Dec 20;148(3):373-9.